摘要
经动脉化疗栓塞(transarterial chemoembolization,TACE)是目前治疗肝细胞癌(hepatocellular carcinoma,HCC)最常用的方法之一。然而,重复进行无效的TACE治疗可能会加重肝功能损伤而影响患者预后。"TACE抵抗(TACE failure/refractoriness)"这一概念,即是在此背景下为避免进行重复无效的TACE治疗而提出的。但已有的多个"TACE抵抗"定义彼此间尚存在分歧,且均存在一定的局限性,对中国HCC人群是否适用也有待商榷。由中国医师协会介入医师分会(Chinese College of Interventionalists,CCI)成立的"TACE抵抗"协作组结合现有的循证医学证据及国内专家意见,于2021年提出了符合中国临床实践的"TACE抵抗"CCI定义及专家共识,旨在使"TACE抵抗"概念更具科学性,从而更好地指导临床实践,以进一步提高中国HCC患者TACE治疗的受益率。
Transarterial chemoembolization(TACE)is the fundamental method for the treatment of unresectable hepatocellular carcinoma(HCC).Nevertheless,ineffective repeat TACE may lead to damage on liver function and therefore have negative effect on long-term prognosis of HCC.The concept of“TACE failure/refractoriness”was then proposed to avoid ineffective repeat TACE.Nevertheless,whether the existing definitions of“TACE failure/refractoriness”are applicable to Chinese HCCs remains to be discussed.Combining reported clinical evidence with experts'opinion,the Chinese College of Interventionalists(CCI)TACE Refractoriness Collaboration Group proposed the CCI definition and expert consensus on TACE refractoriness in 2021.The CCI definition and expert consensus aims to make the concept of TACE refractoriness more scientific and objective,so as to better guide clinical practice of TACE for patients with HCC in China.
作者
中国医师协会介入医师分会临床诊疗指南专委会
倪才方
仲斌演
王万胜
朱海东
Clinical Guidelines Committee of Chinese College of Interventionalists;Ni Caifang(不详;Department of Interventional Radiology,the First Affiliated Hospital of Soochow University,Suzhou 215006,China)
出处
《中华内科杂志》
CAS
CSCD
北大核心
2022年第8期860-866,共7页
Chinese Journal of Internal Medicine
关键词
癌
肝细胞
栓塞
治疗性
抵抗
Carcinoma,hepatocellular
Embolization,therapeutic
Refractoriness
